Are you Dr. Dubow?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 52 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
257 Lafayette Ave
Suite 330
Suffern, NY 10901Phone+1 845-368-8808Fax+1 845-368-5608- Is this information wrong?
Summary
- Dr. Jordan Dubow, MD is a board certified neurologist in Suffern, New York. He is currently licensed to practice medicine in New York, Michigan, and Illinois.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Vascular Neurology, 2010 - 2011
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2003 - 2006
Northwestern University The Feinberg School of MedicineClass of 2003
Certifications & Licensure
IL State Medical License 2004 - 2026
MI State Medical License 2011 - 2012
NY State Medical License 2009 - 2011- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 8 citationsPharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults.David Seiden, Charles Tyler, Jordan Dubow> ;Clinical Therapeutics. 2021 Feb 23
- 99 citationsEfficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophyRobert C. Griggs, J. Phillip Miller, Cheryl R. Greenberg, Darcy Fehlings, Alan Pestronk, Jerry R. Mendell, Richard T. Moxley, Wendy C. King, John T. Kissel, Valerie Cw...> ;Neurology. 2016 Nov 15
- 54 citationsSublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.Robert A. Hauser, C. Warren Olanow, Bruce Dzyngel, Thierry Bilbault, Holly A. Shill, Stuart Isaacson, Jordan Dubow, Albert Agro> ;Movement Disorders. 2016 Sep 1
- Join now to see all
Press Mentions
Paragon Biosciences' CEO Jeff Aronin Names Jordan Dubow New Chief Medical OfficerApril 15th, 2021- Illinois Bill Would Make Telehealth Payment Parity Permanent • Community First Nurses Demand Safety Protections Following Federal Investigation • Medical College Nears AccreditationFebruary 24th, 2021
Avadel Pharmaceuticals Announces Positive Topline Results from Its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with NarcolepsyApril 27th, 2020- Join now to see all
